Table 3.

Clinicodemographic data of chart review patients

Characteristic	Control group (n, %)	COVID group (n, %)	P-valuea
Total	200	200
Age mean ± SD	59.1 ± 14.4	56.9 ± 14.6	0.13
Gender - female	115	102	0.23
Social supports present	165	173	0.46
Tobacco smoking	7	8	0.53
Alcohol use	37	39	0.50
Within low-risk drinking limitsb	31	28
Excess of drinking guidelines	6	11
Distance from clinic
<30km	124	120	0.65
>30km	19	25
Charlson comorbidity scorec (mean ± SD)	3.1 ± 2.1	3.0 ± 2.2	0.54
Liver diagnosis
Cirrhosis	42	53	0.18
Non-alcoholic fatty liver disease	83	76
Viral hepatitis	92	72
Autoimmune hepatitis	5	7
Alcohol liver disease	23	26
Otherd	29	44
Reason for clinic encounter
New patient	47	50	0.62
Active treatment	56	48
Follow-up appointment	95	102

For continuous variables, unpaired T-test was used; for categorical variables Fisher’s exact test was used to calculate P-value.

Defined as 0-2 standard drinks per day, no more than 10 per week for women; 0-3 standard drinks per day, no more than 15 per week for men (41)

A score calculating comorbidity level by assessing the number and severity of 19 pre-defined comorbid conditions.

Other liver diseases included: liver lesions, liver enzyme elevation not yet diagnosed, drug-induced liver injury, Wilson disease, hemochromatosis, biliary cancer, and Caroli disease.